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Abstract
Enteropathy-associated T-cell lymphomas (EATL) are rare and generally aggressive types of peripheral T-cell lymphomas.
Rare cases of primary, small intestinal CD4+ T-cell lymphomas with indolent behavior have been described, but are not well
characterized. We describe morphologic, phenotypic, genomic and clinical features of 3 cases of indolent primary small
intestinal CD4+ T-cell lymphomas. All patients presented with diarrhea and weight loss and were diagnosed with celiac
disease refractory to a gluten free diet at referring institutions. Small intestinal biopsies showed crypt hyperplasia, villous
atrophy and a dense lamina propria infiltrate of small-sized CD4+ T-cells often with CD7 downregulation or loss. Gastric and
colonic involvement was also detected (n = 2 each). Persistent, clonal TCRb gene rearrangement products were detected at
multiple sites. SNP array analysis showed relative genomic stability, early in disease course, and non-recurrent genetic
abnormalities, but complex changes were seen at disease transformation (n = 1). Two patients are alive with persistent
disease (4.6 and 2.5 years post-diagnosis), despite immunomodulatory therapy; one died due to bowel perforation related
to large cell transformation 11 years post-diagnosis. Unique pathobiologic features warrant designation of indolent small
intestinal CD4+ T-cell lymphoma as a distinct entity, greater awareness of which would avoid misdiagnosis as EATL or an
inflammatory disorder, especially celiac disease.
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Introduction
The gastrointestinal (GI) tract is the most common extranodal
site for the occurrence or presentation of lymphomas, the majority
of which are of B-cell origin. [1,2] Peripheral T-cell lymphomas
(PTCLs) account for approximately 15% of primary intestinal
lymphomas. [3,4] Secondary involvement of the GI tract by
different subtypes of T- and NK-lineage lymphomas can be seen in
up to 46% of cases at autopsy. [5] Enteropathy associated T-cell
lymphoma (EATL) types I and II and extranodal NK/T-cell
lymphoma, nasal type, are the most frequent types of lymphomas
presenting with intestinal involvement.[6–8] Rarely, other types of
PTCL such as ALK+ anaplastic large cell lymphoma and gamma-
delta T-cell lymphoma can also arise in the GI tract or involve it
secondarily.[9–11].
Primary T/NK-cell lymphomas of the intestine are associated
with a poor prognosis and a high risk of bowel perforation.[6–8]
However, rare cases of primary GI indolent lymphoproliferative
disorders of CD8+ and CD4+ T-cell lineages have been described,
mostly as sporadic case reports.[12–18] Recently, distinct pheno-
typic, biological and clinical features of indolent NK-cell
lymphoproliferations of the GI tract were delineated in a series
of cases. [19] Although morphologic and clinical features of
indolent lymphomas of the T-cell lineage have been described,
data regarding their immunophenotypic profiles and associated
genomic abnormalities are limited.
Hence, we evaluated the pathologic, genomic and clinical
characteristics of three cases of indolent CD4+ T cell lymphomas,
primarily involving the small intestine. All displayed similar
morphologic, immunophenotypic and clinical features and man-
ifested non recurrent genetic abnormalities, distinct from other
types of primary enteric T-cell lymphomas. [20] In conjunction
with prior reports,[14–17] our findings suggest the existence of a
unique and rare subtype of PTCL not recognized in the current
WHO classification, which warrants greater awareness for correct
diagnosis and optimal management. [20].
Materials and Methods
Case Selection
We searched our departmental database for cases of primary
intestinal T-cell lymphomas diagnosed at our institution over 17
years (1996 and 2012) to identify cases that manifested features
distinct from known types of PTCL. Laboratory test results were
obtained from our laboratory information system and information
regarding clinical presentation, imaging, serologic testing, therapy
and follow-up were obtained from the treating physicians. All
patients provided written informed consent for use of tissue
samples for research, as well as inclusion in the clinical database of
the Celiac Disease Center of Columbia University, in accordance
with the regulations of the Columbia University Human Research
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Protection Program and protocols approved by the Institutional
Review Board of Columbia University, New York, USA.
Morphology, Immunohistochemistry and in situ
Hybridization
Hematoxylin and eosin stained slides were reviewed for cyto-
morphologic evaluation. A comprehensive immunohistochemical
(IHC) staining panel was performed in all cases. Primary
antibodies included CD3, CD5, CD8, CD20 and CD30 (DAKO,
Carpinteria, CA, USA); CD2, CD7, CD25 and CD56, (Vector,
Burlingame, CA, USA); CD4 (BioGenex, San Ramon, CA, USA);
TCRc (ThermoFisher, Waltham, MA, USA); perforin, Bcl6 and
CD10 (Novocastra, Newcastle Upon Tyne, UK); granzyme-B
(Chemicon, Temecula, CA, USA); T-cell intracellular antigen-1
(TIA-1) (Beckman Coulter, Fullerton, CA, USA); Ki-67 and ALK1
(Ventana, Tucson, AZ, USA); FoxP3 and SIRT1 (Abcam,
Cambridge, MA, USA); and PD-1 (Cell Marque, Rocklin, CA,
USA). IHC staining was performed with an automated staining
machine (Universal Staining System, DAKO) after moist heat
induced antigen retrieval and Envision Plus (DAKO) was used for
visualization with Diaminobenzidine as the chromogen, according
to standard protocols. In situ hybridization for EBV encoded small
RNAs (EBER) was performed as per the manufacturer’s recom-
mendations (Ventana, Tucson, AZ, USA).
Flow Cytometry
Four color flow cytometric analysis was performed on cell
suspensions from the tissue biopsies and peripheral blood samples
(FACScan; Becton Dickinson, San Diego, CA, USA) using Cell
Quest software (Becton Dickinson) according to standard proce-
dures. The antigens evaluated included CD2, CD3, CD3e, CD4,
CD5, CD7, CD8, CD10, CD13, CD14, CD16/56, CD19, CD20,
CD30, CD33, CD34, CD45, CD103, TCRb, TCRc and HLA-
DR.
T-cell Receptor Gene Rearrangement Analysis
Polymerase chain reaction to detect T-cell receptor (TCR)b
gene rearrangement was performed on DNA extracted from fresh
or formalin-fixed biopsies from stomach, duodenum, jejunum, and
colon, as well as peripheral blood mononuclear cells using the
‘Biomed-2’ primers (InVivoScribe Technologies, San Diego, CA,
USA), as described previously. [21].
Single Nucleotide Polymorphism (SNP) Array Analysis
Copy number analysis was performed using the Affymetrix
Genome-Wide Human SNP Array 6.0 or CytoScan HD
(Affymetrix, Santa Clara, Calif., USA) on DNA extracted from
tumor samples (Case 1, n= 1; Case 2, n= 3; and Case 3, n= 1,
Tables 1 and 2) and from normal peripheral blood mononuclear
cells (Case 3). Sample preparation, hybridization, and scanning
were performed according to the manufacturer’s specifications.
Analysis was performed using the Affymetrix Chromosome
Analysis Suite 1.0 (ChAS). A` normal reference set of DNA from
50 samples, comprising 25 female and 25 male samples from
individuals with no phenotypic abnormalities and normal karyo-
types, run on the Affymetrix SNP Array 6.0 in our laboratory was
also used for comparison with tumor samples. The reference
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Results
Clinical Characteristics
We identified 3 cases of primary small intestinal CD4+ T-cell
lymphomas, which occurred in 2 males and 1 female (ages 37, 50
and 53), all of western European descent. All patients had prior
evaluations at other institutions for diarrhea and weight loss and
were diagnosed as having celiac disease. They were referred to our
institution for further work-up and management of celiac disease
‘‘non-responsive’’ to a gluten free diet (GFD). Pertinent clinical
features of the patients are summarized in Table 1. On endoscopy,
all patients had nodular mucosa with either flattening of folds or
scalloping, manifesting a mosaic pattern (Fig. 1). Serologic tests for
anti-gliadin and anti-tissue transglutaminase antibodies were
negative on a gluten containing diet. None of the patients lived
in areas endemic for HTLV-1 infection and serology for HTLV-1
was negative in one patient tested (Case 2). No consistent
association with celiac disease-associated HLA-DQ alleles was
seen. Two patients (Case 1 and 3) had mild elevations in LDH and
beta-2 microglobulin at presentation. No other significant
laboratory abnormalities were detected in any patient, with the
exception of one patient (Case 1) who had persistent mild
microcytic anemia (Hgb range 10-8-12.8). All had good perfor-
mance status and low-risk IPI at diagnosis. PET-CT scans showed
mild mesenteric lymphadenopathy with mildly increased FDG-
avidity in one patient at diagnosis (Case 1). Liver lesions were seen
on CT scan in one patient when he developed large cell
transformation (Case 2), which led to multiple small bowel
perforations and death due to sepsis 11 years post diagnosis.































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Duodenum as seen at endoscopy demonstrating
nodular mucosa with scalloping of folds (Case 3).
doi:10.1371/journal.pone.0068343.g001
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Morphology
Multiple biopsies from the stomach, duodenum, jejunum,
ileum, and colon were obtained at diagnosis and follow-up for
all patients (Case 1, number of endoscopic procedures = 5, mean
time interval between procedures = 0.8 years; Case 2, n= 11,
mean time interval = 1 year; Case 3, n = 4, mean time inter-
val = 0.75 years).
All small intestinal biopsies demonstrated crypt hyperplasia and
variable degrees of villous atrophy, ranging from partial to total
(Fig. 2a, Table 2). The most distinct feature was an expansion of
the lamina propria by a patchy or dense sheet-like infiltrate of
small to intermediate-sized lymphocytes (Fig. 2b). The lympho-
cytes had ovoid or irregular nuclei, fine chromatin, indistinct or
small nucleoli, and scant or moderate clear cytoplasm (Fig. 2c).
Only occasional large lymphocytes were noted. Mitoses were rare.
No angiocentricity or angioinvasion was noted and no ulceration
or necrosis was seen. Intraepithelial lymphocytes (IELs) were not
increased (range 10–24/100 epithelial cells). However, duodenal
biopsies from all patients showed foci of crypt destruction and
distinct lymphoepithelial lesions (LELs) in the lower aspects of villi
or crypts (Fig. 2c). Variable numbers of plasma cells, mostly in the
superficial lamina propria, and eosinophils were present. Scat-
tered, small lymphoid aggregates were seen. No granulomas were
observed in any case.
Sections of the proximal small intestinal resection specimen
obtained at the time of exploratory laparotomy for jejunal
perforation, 11 years post-diagnosis of the indolent lymphoma
(Case 2, Table 2) showed persistence of small-sized lymphocytic
infiltrate in the lamina propria, as well as crypt hyperplasia and
total villous atrophy. In addition, an extensive infiltrate of large
atypical lymphocytes was present, extending from the mucosa to
the serosa (Fig. 3a–b). These lymphocytes exhibited marked
nuclear pleomorphism, vesicular nuclei, prominent nucleoli, and
abundant cytoplasm. Scattered bizarre, multinucleated lympho-
cytes, foci of necrosis, and frequent mitotic figures were identified
(Fig. 3c).
Mild lymphocytic infiltrates were seen in the gastric antral and
fundic lamina propria (Case 2 and 3), occasionally rimming the
gastric glands (Fig. 4) and in the lamina propria of the ascending
colon in two patients (Case 2 and 3), which were almost
imperceptible on morphologic evaluation, requiring IHC and
molecular analysis for detection.
Immunophenotype
The phenotypic profile of the neoplastic lymphocytes deter-
mined by IHC and flow cytometry is described in Table 2. A
marked predominance of CD4+ T-cells was observed in all cases.
These lymphocytes expressed CD3 (surface and cytoplasmic) and
CD2. Downregulation or loss of CD5 or CD7 was seen in biopsies
of 2 patients (Fig. 2d–f). The lymphocytes did not express BCL6,
CD10, programmed death 1 (PD-1), Mum1/IRF4, FoxP3, CD8,
CD25, CD30, CD56, TIA-1, perforin, granzyme-B or TCRc. A
mild infiltrate of cytotoxic CD8+ T-cells and B-cells was seen
admixed. PD-1+ lymphocytes were seen as scattered cells in the
lamina propria or forming loose clusters around lymphoid
aggregates, overall accounting for ,5% of all lymphocytes. We
evaluated expression of Sirtuin (silent mating-type information
regulation 2 homolog of Saccharomyces cerevisiae) 1 (SIRT1), a
deacetylase, as a possible cause of FoxP3 non-expression/loss of
expression by the neoplastic lymphocytes. However, only rare
nuclear SIRT1+ lymphocytes were detected in two of the three
cases. The IELs at the tips and along the lateral edges of the villi
expressed CD8, while the LELs in the lower aspects of the villi and
in the crypts were composed of CD4+ T-cells. The Ki-67
proliferation index was low (,5%) in all cases (Fig. 2g) and in
situ hybridization for EBER was negative. Flow cytometry
confirmed the phenotype of the neoplastic lymphocytes (CD4
expression in all cases) and also demonstrated expression of surface
TCRab and lack of CD103 expression.
The neoplastic T-cells in the small intestine resection specimen
from the patient exhibiting large cell transformation 11 years post-
diagnosis and a couple of months prior to his demise (Case 2)
showed additional phenotypic aberrations including expression of
CD30, CD25, Mum1/IRF4, perforin and granzyme-B (Fig. 3). No
ALK1 expression was seen.
No T-cell population displaying an aberrant phenotype was
detected in the peripheral blood of any patient at diagnosis.
However, an abnormal T-cell population was detected in the
peripheral blood at the time of large cell transformation, which
exhibited a phenotype similar to that seen in the small bowel (Case
2).
T-cell Receptor Gene Arrangement Analysis
PCR analysis for TCRb gene rearrangement, performed on
biopsies from multiple sites in all patients, showed clonal products
(Table 2). Identical sized products persisted in all subsequent
samples from each patient, and the large cell transformation,
which occurred in one patient (Case 2), appeared clonally related
to the prior low grade intestinal lymphoma. The only exception
was case 1 where polyclonal products were detected in the
duodenal biopsy 15 years prior to diagnosis of lymphoma. Clonal
products were only detected in the peripheral blood in one patient
(Case 2), commencing four years after diagnosis and persisting till
the patient’s demise, which were identical in size to those detected
in the small intestine.
SNP Array Analysis
All gains and losses were verified manually to determine
erroneous calls and identify mosaic copy number changes (CNCs)
undetected by the software. Analysis was restricted to CNCs
.200 kb in length. Many of these CNCs occurred in regions of
known variation found in normal individuals. For detection of
pathogenic lesions, changes identified by array were compared
with those in the Database of Genomic Variants (http://projects.
tcag.ca/variation) and our own internal reference controls, to
exclude known copy number variants (CNVs). Paired tumor and
normal sample were analyzed for one patient (Case 3). This
patient showed no pathogenic CNCs except subclonal loss of the
X chromosome (monosomy X) seen only in the tumor sample.
Analyses performed on multiple samples at different stages of
disease from one patient (Case 2) detected diverse abnormalities,
including loss on chromosome 19q in a sample obtained shortly
after diagnosis and gains of 1p and 8q in a sample obtained 7 years
later, while analysis of the premortem sample exhibiting large cell
transformation showed multiple gains involving regions on
chromosomes 1, 15, 17, and X and loss of heterozygosity on
chromosome 7q (Table 2). A list of genes in the regions of CNCs
was obtained from the UCSC Genome Browser [NCBI36/hg18
or GRCh37/hg19] (Table S1) and cancer associated genes were
then manually curated and also compared with the Cancer Gene
Census (COSMIC v61 Release; http://www.sanger.ac.uk/
genetics/CGP/Census/). Candidate cancer associated genes are
listed in Table 2.
Discussion
In this report, we describe a series of three cases of a rare
subtype of primary small intestinal CD4+ T-cell lymphoma
Indolent Small Intestinal CD4+ T-Cell Lymphoma
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associated with a relatively indolent disease course. To the best of
our knowledge, a lymphoma with similar features was first
reported by Carbonnel et al. in 1994, which was subsequently
also published as part of a four case series. [14,15] Thereafter,
single case reports by Zivny et al. and Svrcek et al. also described
what appear to be similar types of lymphomas (Table 3). [16,17]
The morphologic and immunophenotypic characteristics of our
and previously published small intestinal CD4+ T-cell lymphomas
Figure 2. Representative photomicrographs of duodenal biopsies. Severe villous atrophy is seen (A) without any increase in intraepithelial
lymphocytes (B). The lamina propria is expanded by a dense infiltrate of predominantly small-sized lymphocytes with evidence of crypt destruction
and a lymphoepithelial lesion (C). On IHC analysis, the lymphocytes are CD4+ (D), CD52 (E), and CD72 (F), and have a low Ki-67 proliferation index
(,5%)(G).
doi:10.1371/journal.pone.0068343.g002
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Figure 3. Section from a small intestinal resection specimen showing large cell transformation (Case 2). Transmural infiltrate of
neoplastic lymphocytes is observed (A). The lamina propria shows admixtures of small and large atypical lymphocytes, including bizarre and
multinucleated forms (B and C). The large lymphocytes express CD4 (D), CD30 (F) and granzyme B (G) and lack CD5 expression (E).
doi:10.1371/journal.pone.0068343.g003
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are distinct from other primary T-cell lymphomas of the GI tract,
such as EATL types I and II. The lymphocytic infiltrates in these
lymphomas comprise a monotonous population of small to
intermediate-sized cells that show mild pleomorphism and virtual
restriction to the lamina propria. A generalized increase in IELs is
usually lacking. Carbonnel et al. and Svrcek et al. reported an
absence of LELs in their cases, however LELs were observed in all
our cases and also in the case reported by Zivny et al.[14–17].
The neoplastic lymphocytes in EATLs can be small or
intermediate in size, but they are of cytotoxic T-cell lineage as
evidenced by cytotoxic granule protein expression, manifesting a
double negative (CD42 CD82) phenotype or displaying variable
degrees of CD8 and CD56 expression. [7,8] EATL type I shows
frequent loss of surface T-cell receptor (TCR)ab and nearly all
cases express CD103, which is considered evidence of its origin
from IELs, as this antigen is expressed by normal IELs. [7,22]
EATL type II comprises lymphomas of both the TCRab and
TCRcd lineages, with a subset of cases showing CD103
expression. [8,23,24] By contrast, all our lymphomas and all prior
reported cases expressed CD4 and surface TCRab (or bF1) and all
evaluated cases lacked CD103 and CD57 expression, consistent
with a helper-inducer T-cell lineage. Of note, at the time of large
cell transformation, which occurred in one of our patients, the
neoplastic cells acquired CD30 and cytotoxic granule antigen
expression and manifested cytomorphologic features indistinguish-
able from EATL type I or anaplastic large cell lymphoma.
The cell of origin of indolent small intestinal CD4+ T-cell
lymphomas is not known at present. The phenotypic findings
argue against an intraepithelial lymphocyte origin or derivation
from natural or induced regulatory T-cells (Tregs). [25,26] It is
known that epigenetic regulation of the FoxP3 gene, as well as post-
translational modifications of the FoxP3 protein, modulate cellular
FoxP3 levels and stability and hence Treg differentiation and
function. [27] Recent studies have shown that acetylation of
FoxP3 by the histone acetyltransferase p300 prevents polyubiqui-
tination and its proteasomal degradation leading to increase
protein stability and increased Treg suppressive capacity, while
deacetylation by Sirtuin 1 (Sirt1), an NAD(+) dependant class III
histone/protein deacetylase, leads to diminution or loss of FoxP3
protein and inhibition of Treg function. [28,29] Thus, we
investigated whether aberrant or deregulated expression of SIRT1
could explain the lack of FoxP3 expression by the neoplastic CD4+
T-cells. Using a specific monoclonal antibody, we found no
convincing evidence of this phenomenon in any of our cases. The
morphologic, phenotypic, and clinical features of indolent small
intestinal CD4+ T-cell lymphomas bear some resemblance to
primary cutaneous CD4+ small/medium sized pleomorphic T-cell
lymphomas, which are thought to be of T-follicular helper (TFH)
cell origin. [30] No expression of CD10, BCL6 or PD-1 was
observed in any of our cases. However, given the diversity and
plasticity of TFH cells, evaluation of additional TFH markers needs
to be investigated in future studies to explore the possible origin of
indolent small intestinal CD4+ T-cell lymphomas from a
particular TFH subtype, or another functional subset or lineage
of CD4+ T-cells. [31].
Presence of phenotypically aberrant lymphocytes and clonal
TCRb gene rearrangements in the stomach and colon in two of
our cases indicated relatively early GI disease dissemination, which
is also a common occurrence in refractory celiac disease (RCD)
type II (a clonal indolent precursor of EATL type I) and EATL
type I, having been reported in up to 78% and 54% of cases,
respectively. [32,33] Zivny et al. and Carbonnel et al. document-
ed cases with neoplastic T-cell infiltration of the stomach, but
colonic involvement was not described in any of the prior reports
(Table 3). [14,16] In contrast to the frequent extra-GI dissemina-
tion at presentation in RCD type II or EATL type I, detected in
44% and 43% of patients, respectively,[7,32234] none of our
patients and previously published cases had evidence of systemic
disease at presentation. However, systemic dissemination does
occur later in disease course. Currently, there are no guidelines
regarding the use of a particular modality to detect and monitor
low level extra-GI disease dissemination in individuals with
indolent small intestinal CD4+ T-cell lymphomas and data
regarding systematic peripheral blood analysis by flow cytometry
and PCR for TCRb rearrangement are lacking. Hence, the time
of occurrence and frequency of peripheral blood involvement is
not known at present. We detected a circulating T-cell clone in the
peripheral blood in only one patient, in the absence of systemic
Figure 4. Representative photomicrograph of a gastric biopsy (Case 3). A mild lymphocytic infiltrate is present (A) with ‘‘rimming’’ of gastric
glands (B). The lymphocytes express CD4 (C).
doi:10.1371/journal.pone.0068343.g004
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disease, four years post-diagnosis, by PCR analysis, but not by flow
cytometry, highlighting the utility of the former modality in disease
monitoring.
The relationship of the described indolent small intestinal CD4+
T-cell lymphomas with other rare types of indolent GI lympho-
proliferative disorders (LPD) published in the English literature is
unclear. The clonal CD4+ T-cell LPDs involving the GI tract
reported by Hirakawa et al. and Egawa et al. showed similar
cytomorphologic features as our and other aforementioned
published cases, but differed with regard to their clinical
presentation and endoscopic features or phenotype. [13,18]
Hirakawa et al. detected multiple polypoid lesions in the stomach,
duodenal bulb and terminal ileum, on endoscopic and radiologic
imaging, in an asymptomatic 47 year old male, which were
covered by normal appearing mucosa. [18] The jejunum was
spared and the colonic mucosa showed apthous ulcers. The
neoplastic lymphocytes at all sampled locations expressed
CD45RO, CD2, CD3, CD4 and CD103(HML-1) and the
lymphoma persisted one year after chemotherapy (cyclophospha-
mide, vindesine, pirarubicin and prednisolone64) and approxi-
mately two years post-diagnosis. Egawa et al. described a low
grade CD3+, CD4+/2, CD562, CD572 and CD103(HML-1)-
T-cell LPD in a 51 year old male, manifesting as multiple, clonally
related, oral and colonic ulcers that had a punched out appearance
and displayed a waxing and waning course over 17 years, with
sparing of the esophagus, stomach and duodenum. [13] The ulcers
were refractory to steroid and antiviral (acyclovir) therapy and
although spontaneous healing of the oral ulcers was seen after two
years of follow-up, the colonic ulcers persisted. Ranheim et al. also
reported an indolent LPD in a 35-year old male that had a
predilection for the oral and colonic mucosa, presenting as clonally
related and recurrent, self-healing ulcerating lesions over a 9 year
period. [12] However, in contrast to the case of Egawa et al., the
neoplastic lymphocytes expressed CD8. A TCRab lineage was
established and a lack CD56 and TIA-1 expression was reported.
The recently described indolent NK-cell LPDs can involve the
small intestine but the neoplastic cells characteristically express
CD56 and lack CD4 expression. [19] Distinguishing indolent
small intestinal CD4+ T-cell lymphoma from RCD type II is
facilitated by the lack of significant intraepithelial lymphocytosis
and predominant lamina propria involvement in the former, as
well as differences in the immunophenotype. [35].
Discriminating between indolent small intestinal CD4+ T-cell
lymphoma and secondary GI involvement by certain subtypes of
PTCL, especially angioimmunoblastic T-cell lymphoma, HTLV1-
associated adult T-cell leukemia/lymphoma, mycosis fungoides
and T-cell prolymphocytic leukemia/lymphoma, can be challeng-
ing on morphologic and phenotypic grounds. [36–41] The
presentation of secondary lymphomatous involvement of the
intestine is generally more acute and there is usually evidence of
disease elsewhere. HTLV-1 serology was negative in one of our
patients tested and in all prior cases where evaluated. [14] As
mentioned above, although all our cases and previously published
cases lacked clinical evidence of systemic disease at presentation,
dissemination to other organs, including liver, skin and lungs,
which occurred later in disease course, could pose difficulties in
ascertaining the primary site of these lymphomas if the patient
presents with long standing disease. [14].
Differentiating inflammatory disorders, especially celiac disease,
inflammatory bowel disease or autoimmune enteropathy from
indolent small intestinal CD4+ T-cell lymphomas can be
diagnostically challenging as the mucosal architectural alterations
can be similar, the neoplastic lymphocytic infiltrate can be patchy
at times and aberrations of the T-cell antigens are absent in some
cases (Table 3). [42,43] Moreover, eosinophilia and epithelioid
granulomas have been reported in the small intestine and other
organs of individuals with these lymphomas, at times in the
absence of significant lymphocytic infiltration. [14,17] Hence, it is
not hard to imagine why all of our and many of the published
cases were misdiagnosed as celiac disease or an inflammatory
disorder, leading to a considerable delay in treatment in many
instances. Phenotypic, molecular and genetic analyses are helpful,
but a high index of clinical suspicion is essential for diagnosing this
subtype of lymphoma.
The demographic features of our patients are similar to those
described for individuals with EATL type I [7] and distinct from
individuals with EATL type II, who tend to be older (7th decade)
and are of diverse ethnicity/race. [8,24] It should be noted that
indolent small intestinal CD4+ T-cell lymphomas can occur in
young adults. [14,17] Patients with such lymphomas can manifest
similar clinical signs as those with EATL types I and II (diarrhea
and weight loss), but the latter more often have an acute
presentation with intestinal obstruction or perforation. [7,8] The
incidence of indolent small intestinal CD4+ T-cell lymphomas is
not known at present. Given the scarcity of reported cases they
appear quite rare. However, given the overlapping morphologic
features with other types of intestinal lymphomas and the clinical
presentation that mimics an inflammatory disorder, we believe
that indolent small intestinal CD4+ T-cell lymphomas are
currently under-recognized, especially in limited resource settings.
A recent Asian study of EATL type II reported two cases of CD4+
T-cell lymphomas, as part of a large series, however specific
pathologic and clinical characteristics of these cases were not
provided. [23] A rising incidence of EATL has also been reported
in the US and it remains to be seen whether inclusion of non-
EATL type I cases such as indolent small intestinal CD4+ T-cell
lymphomas are contributing to this increase. [44].
Our results and the published reports indicate low morbidity
and long survival of patients with indolent small intestinal CD4+
T-cell lymphomas, often exceeding a decade [14,16,17] in contrast
to the median overall survival of 10 and 7 months, respectively, for
patients with EATL types I and II. [7,23] Optimal management of
patients with indolent small intestinal CD4+ T-cell lymphomas is
unclear. Therapy with oral or luminal, non-absorbable steroids led
to good symptom control in our patients, although none achieved
remission, similar to prior reports. [14,16,17] Aggressive therapy
with a variety of chemotherapy regimens in the past has also been
unsuccessful (Table 3). Newer therapeutic modalities are needed
due to the potential for disease progression, transformation and
death.
The etiology of indolent small intestinal CD4+ T-cell lympho-
mas is unclear. Persistent antigenic stimulation as a consequence of
an immune-mediated or infectious disorder is a possibility. One of
our patients demonstrated a polyclonal T-cell infiltrate in
conjunction with villous atrophy 15 years before diagnosis,
suggesting evolution from an antecedent inflammatory disorder.
Due to a lack of material available for evaluation during the
interim period, the precise time of neoplastic transformation in this
patient is unknown. Results of TCRb variable region gene
spectratyping and high-throughput, next generation sequencing
are awaited to investigate the presence of skewed T-cell repertoires
with preferential usage of certain TCRb gene family members or
overrepresentation of certain motifs in the complimentary
determining regions, which could suggest a role of autoantigens
or infectious agents in disease pathogenesis. No association with
celiac-disease associated HLA alleles has been discerned for
indolent small intestinal CD4+ T-cell lymphomas [14], but the
presence of other genetic predisposing factors cannot be ruled out.
Indolent Small Intestinal CD4+ T-Cell Lymphoma
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e68343
These lymphomas lack evidence of EBV infection by in situ
hybridization or serologic assays when analyzed. Only one case in
the series of Carbonnel et al. showed increased EBER+ cells,
which could reflect an expansion of latent EBV infected B-cells in
the setting of lymphoma associated immune dysregulation. [14].
Prior to this report, systematic genomic evaluation of indolent
small intestinal CD4+ T-cell lymphomas was lacking. One case
each, reported previously, displayed trisomy 5 and
t(4;16)(q26;p13.1) by conventional cytogenetic analysis. [14]
Cloning and characterization of the breakpoints of the
t(4;16)(q26;p13.1) led to the identification of the B-cell maturation
antigen (BCMA) gene that was fused to the interleukin (IL)2 gene.
[45] BCMA is a member of the tumor necrosis factor receptor
superfamily, which plays critical roles in B-cell survival and
proliferation, but is not expressed to any significant degree in T-
cells. [46] The pathogenic significance of the chimeric transcript
or the gain or loss of function of either partner gene as a
consequence of the translocation is not known.
Our analysis, using SNP-arrays, indicates relative genomic
stability during the early phases of disease and a lack of recurrent
genetic abnormalities. Aberrations associated with EATL types I
and II, such as amplifications of 9q31.3, deletions of 16q12.1 or 1q
and 5q amplifications, were not detected, with the exception of an
8q gain observed in one sample. [47–49] Interestingly, sequential
analysis of samples from one patient revealed different abnormal-
ities at different time points, suggesting either the presence of an
oligoclonal proliferation, not detectable by PCR analysis, which
underwent therapy-related clonal selection or the occurrence of
distinct cytogenetic abnormalities over time in an otherwise clonal
T-cell lymphoproliferation. Complex cytogenetic abnormalities
observed on disease transformation included gains involving loci
harboring potential oncogenes (Table 2). Of these, STAT3 is a
known oncogene that is deregulated in different types of T-cell
lymphomas, including anaplastic large cell lymphomas and
cutaneous T-cell lymphomas, [50] while ZFX, a gene important
for stem cell renewal, though not implicated in T-cell malignan-
cies, has been shown to have increased expression in solid tumors.
[51–53].
In summary, we report a series of unique primary small
intestinal CD4+ T-cell lymphomas exhibiting an indolent clinical
course that are frequently misdiagnosed as celiac disease. Our
findings, in conjunction with prior reports, suggest that these
lymphomas represent a distinct entity. A comprehensive multi-
modality approach helps in diagnosis. Optimal management is
presently unclear, but close follow-up is recommended as disease
progression and transformation does occur. Greater awareness of
this entity among clinicians and pathologists should lead to the
discovery of more cases, which could facilitate elucidation of the
etiology of these lymphomas and development of targeted therapy.
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